In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 63, Issue 6, Pages -
Publisher
American Society for Microbiology
Online
2019-04-04
DOI
10.1128/aac.02673-18
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
- (2018) A.J. Ullmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
- (2016) Neil R. H. Stone et al. DRUGS
- Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection
- (2016) Francesco Barchiesi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus
- (2015) Zaid Al-Nakeeb et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of Polyene-Azole Combination Therapy against Aspergillosis Using anIn VitroPharmacokinetic-Pharmacodynamic Model
- (2015) Maria Siopi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in anIn VitroPharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum
- (2014) A. Elefanti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model
- (2014) M. Siopi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice
- (2014) J. A. Olson et al. MEDICAL MYCOLOGY
- Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant Aspergillus fumigatus Isolates in a Murine Model of Disseminated Aspergillosis
- (2013) Seyedmojtaba Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens
- (2012) William W. Hope et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroPharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a NewIn VitroDynamic Model
- (2012) R. Al-Saigh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity
- (2012) Karl V. Clemons et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
- (2011) A. Espinel-Ingroff et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients
- (2010) A. H. Groll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis
- (2010) E. Mavridou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections
- (2010) J. A. Olson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis
- (2010) J. M. Lestner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B
- (2010) T. Chang et al. MEDICAL MYCOLOGY
- Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
- (2010) Oliver A. Cornely et al. MYCOSES
- Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis
- (2009) J. W. Mouton et al. MEDICAL MYCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now